Doctors, Optometrists, and Psychologists on LASIK and Suicide
Think LASIK is "safe and effective"? You might change your mind after watching the videos below. Compare these videos to those that document strategies used by Big Pharama to deceive the public about risk Here .
Optometrist David Hartzok on LASIK
Dr. David Hartzok works to save the vision of Lasik victims. Accordingly to Dr. Hartzok, some patients with highly experienced and reputable surgeons still have bad outcomes, thus suggesting that the lasers themselves are responsible for ruining these patient's vision.
FDA Enforcement Diminishing
SOURCE
A spokeswoman for the
FDA ’s
Center for Drug Evaluation and Research told the Center that since
companies have better complied after receiving warning letters, the need for
additional regulatory and enforcement actions has decreased. “We cannot measure
the agency’s enforcement success — nor can we measure industry compliance — by
counting warning letters and other actions individually,” she said. Congress
passed the Food and Drug Administration Amendments Act of 2007 last fall, giving
broader enforcement power to the agency. The impact of the law remains to be
seen.
FDA Enforcement Actions Way Down
Enforcement actions by the
Food and Drug Administration
(FDA), which oversees food and
pharmaceutical products, markedly declined under the
Bush administration . The
number of warning letters issued for various violations dropped by more than
half, from 1,154 in 2000 to 535 in 2005, according to a June 2006 report by
Representative Henry Waxman, a California Democrat, then ranking minority member
of the
House Committee on Government Reform. The “number of seizures of
mislabeled, defective, and dangerous products” plunged by 44 percent, noted the
widely cited report, which also found that officials at FDA headquarters had
“routinely rejected the enforcement recommendations of career field staff.”
Among the curtailed warning letters were those for violations of drug marketing
practices to consumers. "From 2002 through 2005… it took the agency an average
of 4 months to issue a regulatory letter, compared with an average of 2 weeks
from 1997 through 2001," stated a December 2006 report by the
Government Accountability Office
(GAO). "FDA has issued about half as many regulatory letters per year since the
2002 policy change." The FDA has also fallen short in efforts to control “off
label” drug use (using
prescription drugs for nonprescriptive conditions), according to studies
by the Center for Public Integrity and other watchdog groups. The GAO told
Congress in July 2008 that the FDA took inordinate time issuing letters for
offlabel abuses, limiting their effectiveness.
FDA's Medwatch Listing - LASIK
The FDA stated through news media prior to, and at the April 25th ('08)
Ophthalmic Panel Meeting held in Gaithersburg (MD) that it has received only 140
complaints regarding adverse events from LASIK surgeries since LASIK's inception
10 years ago.
These are SOME of the adverse events posted at the
FDA's website , listed by year:
2008 2007 2006 2005 1995 thru 2004
FDA Oversight
SOURCE
"Several Subcommittee investigations resulted in improvements to the public health. The Subcommittee has continued its investigation into the safety of the blood supply and has been instrumental in fostering important reforms at the American Red Cross, and the FDA. The Subcommittee's continuing commitment to improve the generic drug approval process has led to increased vigor in FDA
regulation and enforcement. The Subcommittee continued its efforts to uncover and correct problems in food safety, particularly with regard to imported foods. Meanwhile, the Subcommittee's medical device investigations have highlighted both dangerous devices that were permitted to reach the market through lax approval processes, and potentially life-saving devices that have been delayed
or kept off the market due to bureaucratic infighting or regulatory ineptitude. These efforts resulted in the release of a major report and in substantial reforms at the FDA." 103RD CONGRESS (1993-1994) ENERGY AND COMMERCE COMMITTEE
The Committee's oversight efforts since then have included:
Dingell, Stupak to Investigate FDA’s Medical Device Approval Process
FDA Medical Device Safety
FDA Drug Safety
FDA Food Safety
FDA's Conflicts of Interest
FDA's Compensation Practices
FDA Office of Regulatory Affairs Reorganization
FDA No-Bid Contracts
FDA Drug Safety
SOURCE
Letters (Letters
are in Adobe pdf format)
October 8, 2008
Letter to FDA Commissioner von Eschenbach regarding Actavis Totawa, LLC
Sept. 19, 2008
Letter to Secretary Rice regarding the expansion of Ranbaxy Probe to Include
PEPFAR Program
Sept. 2, 2008
Letter to Schering-Plough and Merck on Vytorin-Cancer Link
Read the Report on the Simvastatin and
Ezetimibe in Aortic Stenosis (SEAS) Study »
August 21, 2008
Letter to
companies Schering-Plough and Merck & Company regarding the safety of
Vytorin and Conflicting Study Data
September 4, 2008 Response »
July 31, 2008
Letter to the head of Wyeth Pharmaceuticals regarding a clinical trial being
conducted in Ghana to test whether moxidectin can inhibit the production of
the parasite associated with river blindness
July 22, 2008
Letter to FDA Commissioner von Eschenbach in regard to drugs sold in the
U.S. by Ranbaxy, Inc.
August 28, 2008 Response »
June 25, 2008
Letters to FDA Commissioner von Eschenbach in regard to adverse events
linked to the the ProHeart 6 canine heartworm treatment
Letter requesting documents »
Letter requesting information »
April 30, 2008
Letter to FDA Commissioner von Eschenbach in regard to the recent outbreak
of Salmonella associated with cantaloupe from Honduras
August 21, 2008, response »
April 11, 2008
Letter to Schering-Plough Corporation and Merck and Co., Inc. in regard to
the Committee's continuing investigation of the ENHANCE trial
April 25, 2008 response »
March 31, 2008
Letter to Johnson & Johnson and Amgen Inc., requesting
documents relating to the marketing strategies of a class of drugs known as
Erythropoiesis-Stimulating Agents (ESAs)
read the Johnson & Johnson Letter »
read the Amgen Inc., Letter »
March 28, 2008
Letter to FDA Commissioner von Eschenbach requesting personnel files of
those FDA employees involved in the failed effort to inspect Chinese
facilities that supplied bulk heparin to Baxter Laboratories
March 19, 2008
Letter to FDA Commissioner von Eschenbach requesting documents relating to
confusion over which Chinese facility supplied bulk heparin
March 12, 2008
Letter to Scientific Protein Laboratories, LLC CEO Strunce requesting
information about the company's involvement in the heparin recall
April 2, 2008 response »
March 31, 2008 response »
March 6, 2008
Letter to FDA Commissioner von Eschenbach in regard to a class of drugs
known as Erythropoiesis-Stimulating Agents
April 16, 2008 response »
March 5, 2008
Letter to HHS Secretary Leavitt in regard to the Agency's offer to access
records related to Dr. von Eschenbach's testimony before the Committee March
22, 2007
Feb. 21, 2008
Letter to Baxter International Inc in regard to Baxter International's
manufactured blood-thinning drug Heparin
March 4, 2008 response »
Feb. 21, 2008
Letter to HHS Secretary Leavitt in regard to Baxter International's
manufactured blood-thinning drug Heparin
May 15, 2008 FDA response »
April 17, 2008 response »
February 25, 2008 response »
Feb. 21, 2008
Letter to FDA Commissioner von Eschenbach in regard to Baxter
International's manufactured blood-thinning drug Heparin
Feb. 15, 2008
Letter to GAO Comptroller General Walker requesting information about the
Agency's oversight study of the FDA
Feb. 14, 2008
Letter to FDA Commissioner von Eschenbach in regard to a Chinese facility
which produces a drug that has been associated with hundreds of adverse
events
April 24, 2008 response »
March 5, 2008 response »
Feb. 14, 2008
Letter to Office of Management and Budget Director Nussle in regard to
findings by the FDA's Science Board as reported in the January 29, 2008
hearing
April 28, 2008 response »
March 18, 2008 response »
Feb. 11, 2008
Letter to FDA Commissioner von Eschenbach requesting further information
regarding the ENHANCE trial
April 10, 2008 response »
March 20, 2008 response »
March 3, 2008 response »
Feb. 7, 2008
Letter to FDA Commissioner von Eschenbach requesting further information
regarding findings by the Science Board
Jan. 24, 2008
Letter to Schering-Plough Corporation and Merck & Co., Inc. in regard to the
withholding of clinical data during the ENHANCE trial
Jan. 24, 2008
Letter to American College of Cardiology CEO Lewin in regard to the
withholding of clinical data during the ENHANCE trial
February 11, 2008 response »
Jan. 24, 2008
Letter to American Heart Association CEO Wheeler in regard to the
withholding of clinical data during the ENHANCE trial
Jan. 22, 2008
Letter to Schering-Plough Corporation and Merck and Co., Inc. in regard to
the Committee's ongoing investigation into Vytorin and the ENHANCE trial
Jan. 22, 2008
Letter to Health and Human Services in regard to the Committee's ongoing
investigation into Vytorin and the ENHANCE trial
February 11, 2008 response »
Jan. 22, 2008
Letter to FDA Commissioner von Eschenbach in regard to the Committee's
ongoing investigation into Vytorin and the ENHANCE trial
Jan. 16, 2008
Letter to GAO Comptroller General Walker requesting more information on a
possible third class of "Behind-the-Counter" drugs
January 24, 2008 response »
Jan. 16, 2008
Letter to Schering-Plough Corporation and Merck and Co., Inc. in regard to
concerns about misleading stat aments in Direct-to-Consumer advertisements
of prescription drugs
Jan. 16, 2008
Letter to FDA Commissioner von Eschenbach in regard to concerns about
misleading stat aments in Direct-to-Consumer advertisements of prescription
drugs
February 1, 2008 response »
Jan. 7, 2008
Letter to CEO and Chairman of the Board Kindler of Pfizer, Inc., in regard
to Dr. Robert Jarvik's endorsement of the drug Lipitor
Dec. 13, 2007
Letter to HHS Secretary Leavitt in regard to the recently signed Memorandum
of Agreements between China and the United States
Dec. 11, 2007
Letter to Schering-Plough Corporation and Merck & Co., Inc. in regard to
withholding of clinical trial data relating to the medical management of
hypercholesterolemia
Nov. 26, 2007
Letter to FDA Commissioner von Eschenbach in regard to a report linking use
of the the drug Trasylol with increased risk of renal failure and mortality
March 25, 2008 response »
February 6, 2008 response »
Oct. 30, 2007
Letter to Housing and Urban Development Inspector General in regard to
allegations of misconduct at the FDA
Oct. 12, 2007
Letter to FDA Commissioner von Eschenbach in regard to observations from a
Committee staff oversight trip to China and India
Oct. 2, 2007
Letter to FDA Commissioner von Eschenbach in regard to imported prescription
drugs and concerns about their ingredients
Oct. 1, 2007
Letter to CDC Director Gerberding in regard to the continued indiscriminate
use of animal antibiotics
Dec. 7, 2007 response »
Aug. 20, 2007
Letter to FDA Commissioner von Eschenbach in regard to FDA inspections of
drug manufacturing plants in China and India
Aug. 1, 2007
Letter to GAO Comptroller General Walker requesting a GAO report on the
FDA's ability to assure the safety of the drug supply
Aug. 16, 2007 response »
July 5, 2007
Letter to FDA Commissioner von Eschenbach in regard to the conduct of FDA
officials in the Avandia matter
August 23, 2007 response »
July 2, 2007
Letter to FDA Commissioner von Eschenbach announcing an investigation of FDA
inspections of foreign manufacturing facilities
June 15, 2007
Letter to HHS Secretary Leavitt regarding concerns about Erythropoiesis-Stimulating
Agents (ESAs) when used at higher than recommended doses
June 2, 2008 response »
April 17, 2008 response »
January 10, 2008 response »
September 27, 2007 response »
March 28, 2007
Letter to HHS Secretary Leavitt in regard to the accuracy of FDA
Commissioner von Eschenbach's testimony at the Committee's March 22, 2007
hearing
April 11, 2007 response »
June 7, 2007 response »
March 20, 2007
Letter to Amgen Chairman, CEO, and President Sharer in regard to the
increased risk of blood clots and tumor growths for patients taking the
drugs trade-named Aranap and Epogen
April 18, 2007 response »
March 20, 2007
Letter to Johnson & Johnson Chairman and CEO Weldon in regard to the
increased risk of blood clots and tumor growths for patients taking the drug
trade-named Procrit
April 18, 2007 response »
August 10, 2007 response »
March 14, 2007
Letter to David Ross in regard to additional questions for the record from
the Feb. 13, 2007 Drug Safety hearing
March 14, 2007
Letter to John Powers in regard to additional questions for the record from
the Feb. 13, 2007 Drug Safety hearing
March 14, 2007
Twenty organizations and individuals write open letter to Congress in regard
to events at the FDA and the implications on the nation's health
March 9, 2007
Letter to Group Pharmaceutical Activities Chairman Rothwell in regard to the
circumstances surrounding the FDA's approval of the Sanofi-Aventis
antibiotic Ketek
June 1, 2007 response »
March 9, 2007
Senator Grassley writes FDA Commissioner von Eschenbach in regard to an FDA
employees testifying before Congress
March 6, 2007
Letter from witness, Ann Marie Cisneros in response to questions posed by
Ranking Member Barton regarding additional questions for the record from the
Feb. 13, 2007 Drug Safety hearing
April 25, 2007
Letter to GAO Director for Public Health and Military Health Care Issues
Crosse in regard to additional questions for the record from the March 22,
2007 Drug Safety hearing
response »
April 25, 2007
Letter to University of Washington Professor Psaty in regard to additional
questions for the record from the March 22, 2007 Drug Safety hearing
May 1, 2007 response »
April 25, 2007
Letter to the FDA Commissioner von Eschenbach in regard to additional
questions for the record from the March 22, 2007 FDA Drug Safety hearing
May 30, 2007 response »
April 24, 2007
Letter to Wake Forest University Professor Furberg in regard to additional
questions for the record from the March 22, 2007 FDA Drug Safety hearing
May 7 , 2007 response »
response »
April 24, 2007
Letter to the Critical Path Institute President and CEO Woosley in regard to
additional questions for the record from the March 22, 2007 FDA Drug Safety
hearing
response »
April 18, 2007
Letter to Commissioner von Eschenbach in regard to the risks associated with
antibiotic-treated animals entering the food supply
June 5, 2007 response »
Feb. 27, 2007
Letter to Copernicus Group Chairman and CEO Hill in regard to circumstances
surrounding the FDA's approval of the Sanofi-Aventis antibiotic Ketek
Feb. 27, 2007
Letter to PPD CEO Eshelman in regard to circumstances surrounding the FDA's
approval of the Sanofi-Aventis antibiotic Ketek
April 13, 2007 response »
March 30, 2007 response
»
March 28, 2007 response »
March 22, 2007 response »
March 15, 2007 response »
March 8, 2007 response »
Feb. 16, 2007
Letter to HHS Secretary Leavitt in regard to the management of drug safety
issues specific to the drug Ketek
July 24, 2007 response »
July 19, 2007 response
»
May 17, 2007 response »
April 25, 2007 response »
April 4, 2007 response »
March 29, 2007 response »
March 1, 2007 response »
Jan. 29, 2007
Letter to FDA Commissioner von Eschenbach in regard to the adequacy of
resources devoted to the Office of Generic Drugs
News Releases
"Dingell,
Stupak Applaud FDA Steps on Food and Drug Safety, Pledge Continued Oversight "
-- November 18, 2008
"GAO
Report Finds FDA’s Foreign Drug Inspection Program Needs Significant Improvement "
-- October 22, 2008
"Dingell,
Stupak Again Question Whether FDA Knowingly Allowed Dangerous Drugs to be Sold
to U.S. Consumers" -- October 8, 2008
"Committee
Expands Ranbaxy Probe to Include PEPFAR Program " -- September 19, 2008
"Dingell,
Stupak Respond to FDA’s Ranbaxy Announcement " -- September 16, 2008
"Dingell,
Stupak Write Schering-Plough and Merch on Vytorin-Cancer Link" -- September
2, 2008
"Dingell,
Stupak Question Drug Makers on Safety of Vytorin and Conflicting Study Data;
Recent Study Links Vytorin to Increased Cancer Risk " -- August 21, 2008
"Dingell,
Stupak Applaud FDA for ESA Label Change" -- August 5, 2008
"Dingell,
Stupak Comment on Latest Developments in FDA Salmonella Investigation" --
July 21, 2008
"Dingell,
Stupak to Investigate Ranbaxy Drug Approvals" -- July 22, 2008
"Dingell,
Stupak Comment on Results of New Vytorin Study" -- July 22, 2008
"Dingell,
Stupak Question Whether FDA Knowingly Allowed Potentially Unsafe & Ineffective
Drugs into the U.S. Marketplace" -- July 17, 2008
"Dingell,
Stupak Question FDA’s Re-approval of ProHeart6" -- June 25, 2008
"After
Review of ENHANCE Trial Documents, Dingell, Stupak Express 'Serious Concerns'"
-- April 15, 2008
"Committee
Panel to Hold Hearings on Heparin Failures" -- March 19, 2008
"How Much
Will it Cost to Adequately Fund FDA’s Core Programs? Energy & Commerce Leaders
Release Recommendations of Former Members and Advisors to FDA’s Science Advisory
Board" -- February 26, 2008
read the letter to Committee Chairmen »
read the FDA's Science Board Report »
"Continues
Investigation into Celebrity Drug Endorsements" -- February 7, 2008
"Dingell
Blasts Bush’s Health Care Cuts" -- February 4, 2008
"Dingell,
Stupak Comment on FDA Plan for Overseas Inspections" -- January 25, 2008
"Dingell,
Stupak Question Merck/Schering-Plough’s Sponsorship of American College of
Cardiology and American Heart Association" -- January 24, 2008
"Dingell,
Stupak Comment on Decision to Pull Vytorin Ads" -- January 23, 2008
"Dingell,
Stupak Raise Concerns, Questions on ENHANCE Trial" -- January 16, 2008
"Dingell,
Stupak to Continue ENHANCE Trial Investigation" -- January 14, 2008
"Dingell,
Stupak Not Satisfied With FDA Response to Committee Requests; Will Consider
Other Options to Fulfill Requests " -- May 24, 2007
"Dingell,
Stupak Question FDA & Glaxo for Failing to Warn Diabetics of Dangers of Avandia"
-- May 21, 2007
"Dingell,
Stupak Call on Amgen, Johnson & Johnson to Suspend Direct-to-Consumer Marketing
for Anemia Drugs" -- March 21, 2007
Hearing Materials
Statements
May 8, 2008
Chairman Stupak at the hearing entitled "Direct-to-Consumer Advertising:
Marketing, Education, or Deception?"
May 8, 2008
Chairman
Dingell at the hearing entitled "Direct-to-Consumer Advertising: Marketing,
Education, or Deception?"
April 29, 2008
Chairman
Dingell at the hearing entitled "The Heparin Disaster: Chinese Counterfeits
and American Failures"
April 29, 2008
Chairman Stupak at the hearing entitled "The Heparin Disaster: Chinese
Counterfeits and American Failures"
April 22, 2008
Chairman Stupak at the hearing entitled "FDA’s Foreign Drug Inspection
Program: Weaknesses Place Americans at Risk"
April 22, 2008
Chairman
Dingell at the hearing entitled "FDA’s Foreign Drug Inspection Program:
Weaknesses Place Americans at Risk"
February 12, 2008
Chairman
Dingell at the hearing entitled "Ketek Clinical Study Fraud: What Did
Aventis Know"
February 12, 2008
Chairman Stupak at the hearing entitled "Ketek Clinical Study Fraud: What
Did Aventis Know"
January 29, 2008
Chairman
Dingell at the hearing entitled "Science and Mission at Risk: FDA’s
Self-Assessment"
January 29, 2008
Chairman Stupak at the hearing entitled "Science and Mission at Risk: FDA’s
Self-Assessment"
March 22, 2007
Chairman
Dingell at the hearing entitled "The Adequacy of the FDA Efforts to Assure
the Safety of the Drug Supply Part II"
March 22, 2007
Chairman Stupak at the hearing entitled "The Adequacy of the FDA Efforts to
Assure the Safety of the Drug Supply Part II"
February 13, 2007
Chairman Stupak at the hearing entitled "The Adequacy of FDA Efforts to
Assure the Safety of the Drug Supply"
February 13, 2007
Chairman
Dingell at the hearing entitled "The Adequacy of FDA Efforts to Assure the
Safety of the Drug Supply"
November 1, 2007
Chairman
Dingell at the hearing entitled "FDA Foreign Drug Inspection Program: A
System At Risk"
November 1, 2007
Chairman Stupak at the hearing entitled "FDA Foreign Drug Inspection
Program: A System at Risk"
Other Documents